This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.
What are Antibody Therapies?
Antibody therapies augment the naturally occurring antibodies in our immune system that help the immune system recognize infections.3 Antibodies have been developed to help identify and attack malignant cells in multiple myeloma, and in other cancers. Multiple novel combinations of antibody therapeutics are now available for the management of multiple myeloma. These include1,4-6:
- Signaling lymphocyte activation molecular family 7 (SLAMF7) antibodies
- Anti-CD38 antibodies
- B-cell maturation antigen (BCMA)-targeted antibody-drug conjugates
In addition to these therapies, multiple other therapies are now in development called bispecific antibodies. These antibodies can help bring together T cells, which are immune cells involved in targeting and destroying cancer cells, and specific receptors on cancer cells. In this way, bispecific antibodies can help the immune system recognize and destroy cancer. One target on cancer cells in multiple myeloma is known as B-cell maturation antigen (BCMA). With approval secured for one bispecific antibody, teclistamab, additional bispecific antibodies targeting BCMA are in active development for multiple myeloma, including7,8:
- Linvoseltamab (REGN5458)
- Alnuctamab (CC-93269)
- Elranatamab (PF-06863135)
If you have already received multiple earlier lines of therapy, discussing these therapies with your physician might give rise to consideration of clinical trial opportunities in developing lines of therapy.8